ACTIVITY IN THE THIRD QUARTER OF 2015
(Unaudited data)
DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER(VARIATION AT CURRENT RATE)
1
st Quarter
2ndQuarter
3rdQuarter
thousands of euros
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
France
82,749
89,584
+ 8.3%
74,269
76,864
+ 3.5%
92,466
97,767
+ 5.7%
Europe (excluding France)
39,967
40,657
+ 1.7%
33,570
29,943
- 10.8%
62,758
50,614
- 19.4%
North America
12,662
17,193
+ 35.8%
10,625
12,894
+ 21.4%
13,109
16,055
+ 22.5%
Other countries
4,831
4,622
- 4.3%
2,943
3,816
+ 29.7%
3,779
3,594
- 4.9%
Group total
140,209
152,056
+ 8.4%
121,407
123,517
+ 1.7%
172,112
168,030
- 2.4%
1stQuarter
2ndQuarter
3rdQuarter
thousands of euros
2014
2015
Var. 15/14
2014
2015
Var. 15/14
2014
2015
Var. 15/14
Non-proprietary Homeopathic Medicines
77,919
79,191
+ 1.6%
73,072
74,354
+ 1.8%
72,957
73,677
+ 1.0%
OTC Specialties
62,196
72,880
+17.2%
48,058
49,030
+ 2.0%
99,025
94,328
- 4.7%
Other
94
-15
-
277
133
- 52.0%
130
25
- 80.8%
Group total
140,209
152,056
+ 8.4%
121,407
123,517
+ 1.7%
172,112
168,030
- 2.4%
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER2015
thousands of euros
2014
2015
Variation at
current exchange
rates
Variation at constant exchange
rates
France
249,484
264,215
+ 5.9%
+ 5.9%
Europe (excluding France)
136,295
121,214
- 11.1%
- 7.1%
North America
36,396
46,142
+ 26.8%
+ 7.1%
Other countries
11,553
12,032
+ 4.1%
+ 6.7%
Group total
433,728
443,603
+ 2.3%
+ 1.9%
thousands of euros
2014
2015
Variation at
current exchange
rates
Variation at constant exchange
rates
Non-proprietary Homeopathic Medicines
223,948
227,222
+ 1.5%
+ 0.5%
OTC Specialties
209,279
216,238
+ 3.3%
+ 3.6%
Other
501
143
- 71.5%
- 48.9%
Group total
433,728
443,603
+ 2.3%
+ 1.9%
HIGHLIGHTS OF THE THIRD QUARTER
Sales revenue in the 3rdquarter of 2015 are decreasing by 2.4% in comparison to 2014 (-1% at constant rate) with a revenue growth in France and the USA, but in decline mainly in Russia and to a lesser extent in Italy and Poland.
Boiron announced its plan to locate its future logistic platform in the town of Les Olmes, near Tarare in the West of Lyon.
Meanwhile, construction work for the site extension of Messimy have begun.
Boiron put on the French market a new cough syrup, Stodaline®.
OUTLOOK
Boiron continues its involvement in the development of homeopathy in the world.
Given the development of the activity at the end of September 2015 and the unpredictability of seasonal pathology of the last quarter, the operational income may not reach the same level as in 2014.
Our next update: January 21, 2016 at market close, publication of the sales revenue for the year 2015. Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
